Logout Login Cart iconShop
Contact Sales

Search

Filters

Content Type

Products

Clear Filters

Search Results for "【Order On Telegram: @Chem2Door】Where To Buy Lunesta In San Diego,.7093"

Looking for quality documents?
external link icon
Repligen Receives Notice of Allowance for Recombinant Protein A Patent
external link icon
Repligen Reports Preliminary Fiscal Year 2011 Financial Results and Financial Guidance and Development Goals for Fiscal Year 2012
external link icon
Repligen Reports Financial Results for the Year 2014 and Issues 2015 Financial Guidance
- Year 2014 Product Sales Increase 27% to a Record $60.4 Million - - Fourth Quarter Product Sales Increase 49% to $15.4 Million - - Conference Call and Webcast Today at 8:30 a.m. EDT - WALTHAM, Mass., March 13, 2015 (GLOBE NEWSWIRE) - Repligen Corporation (Nasdaq:RGEN) today reported financial results for the fourth quarter and year ended December 31, 2014. Below are the Company's performance highlights for these periods, followed by financial guidance for the year 2015 and access information for today's webcast and conference call. Walter C. Herlihy, Ph.D., President and Chief Executive Officer said, "2014 was an outstanding year for Repligen. We started the year with a focus on accelerating growth and expanding margins in our core business, while investing in our commercial organization and pursuing bioprocessing acquisition opportunities. We executed on all fronts, delivering 27% product sales growth and a 30% increase in gross profit bolstered by our acquisition of the ATF System
external link icon
Repligen Reports First Quarter Fiscal Year 2011 Financial Results Product Sales Increase by 73%
external link icon
Repligen Reports Preliminary Fiscal Year 2010 Financial Results and Provides Financial Guidance and Development Goals for Fiscal Year 2011
external link icon
Repligen Reports Third Quarter 2025 Financial Results and Updates Full Year 2025 Financial Guidance
Revenue of $189 million, year-over-year increase of 22% as reported and 18% organic with double-digit reported growth across all franchises Orders increased sequentially and greater than 20% year-over-year Increasing revenue guidance to a range of $729 to $737 million, which represents 14% -15.5% year-over-year non-COVID organic growth

WALTHAM, Mass., Oct. 28, 2025 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its third quarter of 2025, covering the three- and nine- month periods ended September 30, 2025. Provided in this press release are financial performance highlights, updates to our guidance for the full year 2025 and access information for today’s webcast and conference call. Olivier Loeillot, President and Chief Executive Officer of Repligen said, “We had another outstanding quarter in Q3 with 18% organic growth. We are thrilled with the momentum we
external link icon
Repligen Reports First Quarter 2023 Financial Results and Updates Full Year 2023 Financial Guidance
Reports first quarter revenue of $182.7 million, with base business growth of 4% as reported and 7% at constant currency Reports first quarter gross margin of 55.2% on both GAAP and adjusted (non-GAAP) basis Closed on acquisition of single-use bag manufacturer FlexBiosys Inc. in April
WALTHAM, Mass., May 02, 2023 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its first fiscal quarter ended March 31, 2023. Provided in this press release are financial highlights for the quarter, updates to our financial guidance for the year 2023 and access information for today’s webcast and conference call. Tony J. Hunt, President and Chief Executive Officer of Repligen said, “Given the challenging macro environment, I am very happy with our overall performance in the first quarter, with year-over-year base business growth of 7% at constant currency. In the quarter, we saw strong
external link icon
Repligen Reports Third Quarter 2022 Financial Results and Updates Full Year 2022 Financial Guidance
Reports revenue of $200.7 million for the quarter, representing year-over-year growth of 13% as reported, 19% at constant currency and 16% organic
Delivers base business growth of 29% for the quarter Expands Process Analytics portfolio with DRS Daylight Solutions agreement
WALTHAM, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its third quarter of 2022. Provided in this press release are financial highlights for the three- and nine- month periods ended September 30, 2022, updates to our financial guidance for the year 2022 and access information for today’s webcast and conference call. Tony J. Hunt, President and Chief Executive Officer said, “I’m very pleased with our performance for the third quarter, with reported revenue of $201 million reflecting overall revenue growth of approximately 13% year-over-year, and 19% at constant
external link icon
Repligen Reports First Quarter 2022 Financial Results and Updates Full Year 2022 Financial Guidance
—Record revenue of $206.4 million for the quarter, and year-over-year growth of 45% as reported and 48% at constant currency —Organic revenue growth of 44% for the quarter and base business growth of 37% —Growth driven by combination of base business strength, COVID-related demand, and acquisition revenue
WALTHAM, Mass., April 27, 2022 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its first quarter ended March 31, 2022. Provided in this press release are financial highlights for the quarter, updates to our financial guidance for the year 2022 and access information for today’s webcast and conference call. Tony J. Hunt, President and Chief Executive Officer said, “We delivered on another outstanding quarter for the company with over $206 million in revenue and 44% organic growth. We were especially pleased with the momentum in our base business, which delivered
external link icon
Repligen Reports Third Quarter 2021 Financial Results and Updates Full Year 2021 Financial Guidance
Reports record revenue of $178.2 million for the quarter, representing year-over-year growth of 89% and organic growth of 77% Raises revenue guidance to $655-$665 million for full year 2021 Completes acquisition of affinity ligands innovator Avitide Inc.
WALTHAM, Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its third quarter of 2021. Provided in this press release are financial highlights for the three- and nine- month periods ended September 30, 2021, updates to our financial guidance for the fiscal year 2021 and access information for today’s webcast and conference call. Tony J. Hunt, President and Chief Executive Officer said, “We delivered strong overall performance during the third quarter, with record revenue of $178 million and organic growth of 77% year-over-year. Our base business delivered 49% organic growth, reflecting an
Close modal

A new look. A better way to explore Repligen.

We’ve redesigned Repligen.com to help you find the right solutions faster, with greater clarity and less effort.

Find what you need faster
Get to the right information with quicker site speed

Explore the site with ease
Navigate easily with an intuitive, simple site structure

Access product details instantly
Find products and resources faster, in fewer clicks

Get support when you need it
Connect with our team when you need support